An observational study in Acute Respiratory Failure With Hypoxia and Hypoxemia, sponsored by Hôpital Louis Mourier. Status unknown at 10 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-20.
Sponsored by Hôpital Louis Mourier · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Hypoxia with a site in France — 17 open to participants now, 17 under way, 1 of them phase 3. Hypoxia · France.
Among the 71 studies in Hypoxia with a site in France, this one is the 12th largest by planned enrollment of the 21 observational ones that give a count, is one of 3 that started in 2018, is one of 21 observational ones, and was the 33rd registered.
1,078 studies on the registry are indexed under Hypoxia; 214 are open to participants now.
Browse Hypoxia studies →17 of the 71 studies in Hypoxia with a site in France are open now. Recruiting first, the newest first:
Poitiers University Hospital · Sites in France
Ages 18–45 · Healthy volunteers
University Hospital, Grenoble · Sites in France
Ages 18–55 · Healthy volunteers
Universite du Littoral Cote d'Opale · Sites in France
Ages 18–65 · Healthy volunteers
University Hospital, Strasbourg, France · Sites in France
Ages 0 days–1 days
Poitiers University Hospital · Sites in France
Ages 18–75 · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 126 Hypoxia studies recruiting now, 53 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 3 · Phase 4 5
First in 1963; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 79 across 278 observational studies indexed under Hypoxia.
Median enrollment 41 across the 50 interventional studies, 101 across the 21 observational. Of the 38 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 71 have an industry lead sponsor. The 10 most frequent:
Hôpital Louis Mourier is the lead sponsor of 11 studies on the registry; none are open to participants now.
Hôpital Louis Mourier has 2 studies filed under Hypoxia — fewer than ten, so there is no comparison to draw.
4 of the studies in Hypoxia with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07516028Universite du Littoral Cote d'OpaleBrain Connectivity and Corticospinal Excitability in Response to Moderate Hypoxia | 2026-12-20 |
| NCT07585227Direction Centrale du Service de Santé des ArméesStudy of the Effects of Acute Exposure to Moderate Altitude Hypoxia on Prospective Memory. | 2026-12-31 |
| NCT05525312University Hospital, MontpellierComparison of Two Strategies of One-lung Ventilation in Patients Undergoing Carcinological Lung Resection Surgery. | 2027-03-20 |
| NCT07072975Centre Hospitalier Universitaire, AmiensCPOD Patient's Tolerance of Intermittent Exercise With Inter-exercise Recovery Under Normoxic Hypoxia | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 71 studies in Hypoxia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Although many studies have investigated the clinical benefits of nasal high flow during acute hypoxemic respiratory failure, there is no data (and even less so recommendations) on how to best conduct this technique, including its initiation and its weaning periods. Investigators will assess in a multicenter, observational study, the way clinicians use nasal high flow therapy in patients with acute respiratory failure in order to try identify one or more strategies that may be then compared in an interventional study.
Nasal high flow oxygen therapy is increasingly used as a first-line treatment for hypoxemic acute respiratory failure, because of its remarkable tolerance (in comparison with NIV) and its physiological effects (nasopharyngeal dead space washout, positive end-expiratory pressure effect with possible alveolar recruitment, better matching with the patient's inspiratory flow, more reliable and adjustable FiO2); that together contribute to a reduction in respiratory workload and better oxygenation.
Although many studies have investigated the clinical benefits of nasal high flow during acute hypoxemic respiratory failure, there are no data (and even less recommendations) on how to best conduct this technique, including its initiation and its weaning periods.
Because different approaches exist among clinicians, investigators believe that a multicenter observational study that would collect data regarding the different ways high flow is conducted in patients with acute respiratory failure is necessary before performing an interventional study that would test and compare different strategies in order to answer the question: what are the best strategies (in terms of flow and FiO2 settings) to initiate and to wean high-flow oxygen therapy in patients with acute respiratory failure?
Investigators will assess in a multicenter, observational study, the way clinicians use nasal high flow therapy in patients with acute respiratory failure in order to try identify one or more strategies that may be then compared in an interventional study.
Adult patients admitted to an ICU or an intermediate care unit, who require nasal high flow oxygen therapy for acute hypoxemic respiratory failure
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Non-inclusion Criteria:
Exclusion criteria
values of gas flow over time (in liters per minute)
values of gas flow set on the device of nasal high flow will be monitored over time so as to describe how physicians set and modify this parameter during treatment with nasal high flow
Time frame: entire duration of high flow therapy (5 to 7 days)
values of fraction in inspired oxygen (FiO2) over time (between 0.21 and 1.0)
values of FiO2 set on the device of nasal high flow will be monitored over time so as to describe how physicians set and modify this parameter during treatment with nasal high flow
Time frame: entire duration of high flow therapy (5 to 7 days)
respiratory rate (breath per minute)
values of respiratory rate upon initiation of nasal high flow and at each change of nasal high flow parameters (gas flow or FiO2) will be monitored.
Time frame: entire duration of high flow therapy (5 to 7 days)
pulse oximetry (SpO2) (percentage)
values of oxgen saturation upon initiation of nasal high flow and at each change of nasal high flow parameters (gas flow or FiO2) will be monitored.
Time frame: entire duration of high flow therapy (5 to 7 days)
values of the Respiratory rate Oxygenation indeX ("ROX") index defined as the ratio of pulse oximetry over fraction of inspired oxygen to respiratory rate
values of the "ROX" index will be monitored at different time points (2, 6 and 12 hours after nasal high flow therapy initiation)
Time frame: 12 hours
Plan to share: Undecided
Started Jul 2018 (actual). Primary completion is estimated for Oct 2018, 3 months after the start.
Of 125 non-industry observational studies under Hypoxia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 74. This study's planned 3 months is below that.
Counting every sponsor, half of 155 studies reached it within 14 months; a quarter within 3 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hôpital Louis Mourier